Biomedical Research

Objective: To explore clinical effect of atorvastatin-trimetazidine combined treatment of patients with coronary heart diseases.

Methodology: A total of 98 patients with coronary heart diseases accepted by our hospital from February 2016 to June 2017 were divided into two groups according to random principle, namely reference group (n=49) and study group (n=49). Patients in the reference group accepted atorvastatin treatment while those in the study group accepted atorvastatin-trimetazidine combined treatment. Then, a statistical comparison in the aspects of clinical effect, blood lipid index, cardiac function index, and occurrence of adverse reactions between the two groups was carried out.

Results: Overall effective rate of patients in the study group is 93.88%, which is significantly different from that of patients in the reference group (79.59%) (P<0.05). Triglyceride (TG), Total Cholesterol (TC), Low-Density Lipoprotein Cholesterol (LDL-C) and High-Density Lipoprotein Cholesterol (HDLC) are significantly lower than those of patients in the reference group (P<0.05). Left Ventricular Ejection Fractions (LVEF) of patients in the study group were significantly larger than those of patients in the reference group (P<0.0) while their Left Ventricular End-Systolic Dimension (LVESD) and Left Ventricular End-Diastolic Dimension (LVEDD) are both smaller than those of patients in the reference group (P<0.05).

Conclusion: Clinical effect of atorvastatin-trimetazidine combined treatment on patients with coronary heart diseases is prominent and can effectively improve blood lipid level and cardiac functions of patients. Such combination is a therapeutic schedule deserving clinical promotion and application because it is safe and reliable.

Author(s): Ji-Dong Song, Li-Li Wang
Abstract | Full-Text | PDF

Share this